The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia

Biological Psychiatry

Volumn 81, Issue 1, 2017, Pages 9-20

  Howes, Oliver D ^a,b   McCutcheon, Robert ^a,b   Owen, Michael J ^c   Murray, Robin M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Dopamine; Etiology; Genetics; Neuroimaging; PET; Prodrome; Psychosis; Schizophrenia; Stress

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; NEUROTRANSMITTER; DRD2 PROTEIN, HUMAN;

ACUTE STRESS; BRAIN CORTEX; CHRONIC STRESS; COGNITION; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ENVIRONMENTAL FACTOR; GENE; GENETIC POLYMORPHISM; GENETICS; HEREDITY; HIGH RISK POPULATION; HUMAN; MENTAL STRESS; MESENCEPHALON; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SOCIAL ISOLATION; STRESS; ANIMAL; BRAIN; COMPLICATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; BRAIN; CORPUS STRIATUM; DOPAMINE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE D2; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STRESS, PSYCHOLOGICAL;

EID: 84997285715     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2016.07.014     Document Type: Review

References (135)

1. 1 Meltzer, H.Y., Stahl, S.M., The dopamine hypothesis of schizophrenia: A review. Schizophr Bull 2 (1976), 19–76.
2. 2 Davis, K.L., Kahn, R.S., Ko, G., Davidson, M., Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 148 (1991), 1474–1486.
3. 3 Howes, O.D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., Kapur, S., The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 69 (2012), 776–786.
4. 4 Angrist, B.M., Gershon, S., The phenomenology of experimentally induced amphetamine psychosis–Preliminary observations. Biol Psychiatry 2 (1970), 95–107.
5. 5 Connell, P., Amphetamine psychosis. Br Med J, 1(5018), 1957, 582.
6. 6 Carlsson, A., Lindqvist, M., Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 20 (1963), 140–144.
7. 7 Seeman, P., Lee, T., Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188 (1975), 1217–1219.
8. 8 Lee, T., Seeman, P., Elevation of brain neuroleptic/dopamine receptors in schizophrenia. Am J Psychiatry 137 (1980), 191–197.
9. 9 Seeman, P., Kapur, S., Schizophrenia: More dopamine, more D2 receptors. Proc Natl Acad Sci U S A 97 (2000), 7673–7675.
10. 10 Kim, E., Howes, O.D., Kapur, S., Molecular imaging as a guide for the treatment of central nervous system disorders. Dialogues Clin Neurosci 15 (2013), 315–328.
11. 11 Chen, K.C., Yang, Y.K., Howes, O., Lee, I.H., Landau, S., Yeh, T.L., et al. Striatal dopamine transporter availability in drug-naive patients with schizophrenia: A case-control SPECT study with [(99m)Tc]-TRODAT-1 and a meta-analysis. Schizophr Bull 39 (2013), 378–386.
12. 12 Taylor, S.F., Koeppe, R.A., Tandon, R., Zubieta, J.K., Frey, K.A., In vivo measurement of the vesicular monoamine transporter in schizophrenia. Neuropsychopharmacology 23 (2000), 667–675.
13. 13 Zubieta, J.K., Taylor, S.F., Huguelet, P., Koeppe, R.A., Kilbourn, M.R., Frey, K.A., Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects. Biol Psychiatry 49 (2001), 110–116.
14. 14 Howes, O.D., Williams, M., Ibrahim, K., Leung, G., Egerton, A., McGuire, P.K., Turkheimer, F., Midbrain dopamine function in schizophrenia and depression: A post-mortem and positron emission tomographic imaging study. Brain 136 (2013), 3242–3251.
15. 15 Mizrahi, R., Kenk, M., Suridjan, I., Boileau, I., George, T.P., McKenzie, K., et al. Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use. Neuropsychopharmacology 39 (2013), 1479–1489.
16. 16 Pogarell, O., Koch, W., Karch, S., Dehning, S., Müller, N., Tatsch, K., et al. Dopaminergic neurotransmission in patients with schizophrenia in relation to positive and negative symptoms. Pharmacopsychiatry 45:suppl 1 (2012), S36–S41.
17. 17 Kegeles, L.S., Abi-Dargham, A., Frankle, W.G., Gil, R., Cooper, T.B., Slifstein, M., et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 67 (2010), 231–239.
18. 18 Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L.S., et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 97 (2000), 8104–8109.
19. 19 Abi-Dargham, A., van de Giessen, E., Slifstein, M., Kegeles, L.S., Laruelle, M., Baseline and amphetamine-stimulated dopamine activity are related in drug-naïve schizophrenic subjects. Biol Psychiatry 65 (2009), 1091–1093.
20. 20 Weinberger, D.R., Berman, K.F., Daniel, D.G., Mesoprefrontal cortical dopaminergic activity and prefrontal hypofunction in schizophrenia. Clin Neuropharmacol 15:suppl 1 (1992), 568A–569A.
21. 21 Slifstein, M., van de Giessen, E., Van Snellenberg, J., Thompson, J.L., Narendran, R., Gil, R., et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: A positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry 72 (2015), 316–324.
22. 22 Kambeitz, J., Abi-Dargham, A., Kapur, S., Howes, O.D., Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: Systematic review and meta-analysis of imaging studies. Br J Psychiatry 204 (2014), 420–429.
23. 23 Yung, A.R., Phillips, L.J., Yuen, H.P., Francey, S.M., McFarlane, C.A., Hallgren, M., McGorry, P.D., Psychosis prediction: 12-Month follow up of a high-risk (“prodromal”) group. Schizophr Res 60 (2003), 21–32.
24. 24 McGlashan, T.H., Zipursky, R.B., Perkins, D., Addington, J., Miller, T., Woods, S.W., et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 163 (2006), 790–799.
25. 25 Ruhrmann, S., Bechdolf, A., Kühn, K.U., Wagner, M., Schultze-Lutter, F., Janssen, B., et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry Suppl 51 (2007), s88–s96.
26. 26 Sumiyoshi, T., Kurachi, M., Kurokawa, K., Yotsutsuji, T., Uehara, T., Itoh, H., Saitoh, O., Plasma homovanillic acid in the prodromal phase of schizophrenia. Biol Psychiatry 47 (2000), 428–433.
27. 27 Suridjan, I., Rusjan, P., Addington, J., Wilson, A.A., Houle, S., Mizrahi, R., Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task. J Psychiatry Neurosci 38 (2013), 98–106.
28. 28 Mizrahi, R., Addington, J., Rusjan, P.M., Suridjan, I., Ng, A., Boileau, I., et al. Increased stress-induced dopamine release in psychosis. Biol Psychiatry 71 (2012), 561–567.
29. 29 Bloemen, O.J., de Koning, M.B., Gleich, T., Meijer, J., de Haan, L., Linszen, D.H., et al. Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at ultra high risk for psychosis. Eur Neuropsychopharmacol 23 (2013), 126–132.
30. 30 Howes, O.D., Montgomery, A.J., Asselin, M.-C., Murray, R.M., Valli, I., Tabraham, P., et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 66 (2009), 13–20.
31. 31 Egerton, A., Chaddock, C.A., Winton-Brown, T.T., Bloomfield, M.A., Bhattacharyya, S., Allen, P., et al. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: Findings in a second cohort. Biol Psychiatry 74 (2013), 106–112.
32. 32 Howes, O.D., Bose, S.K., Turkheimer, F., Valli, I., Egerton, A., Valmaggia, L.R., et al. Dopamine synthesis capacity before onset of psychosis: A prospective [18F]-DOPA PET imaging study. Am J Psychiatry 168 (2011), 1311–1317.
33. 33 Howes, O., Bose, S., Turkheimer, F., Valli, I., Egerton, A., Stahl, D., et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis : A PET study. Mol Psychiatry 16 (2011), 885–886.
34. 34 Allen, P., Chaddock, C.A., Howes, O.D., Egerton, A., Seal, M.L., Fusar-Poli, P., et al. Abnormal relationship between medial temporal lobe and subcortical dopamine function in people with an ultra high risk for psychosis. Schizophr Bull 38 (2012), 1040–1049.
35. 35 Fusar-Poli, P., Howes, O.D., Allen, P., Broome, M., Valli, I., Asselin, M.-C., et al. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry 16 (2011), 67–75.
36. 36 Cannon, M., Ph, D., Jones, P.B., Murray, R.M., Obstetric complications and schizophrenia : Historical and meta-analytic review. Am J Psychiatry 159 (2002), 1080–1092.
37. 37 Di Forti, M., Marconi, A., Carra, E., Fraietta, S., Trotta, A., Bonomo, M., et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: A case-control study. Lancet Psychiatry 2 (2015), 233–238.
38. 38 Varese, F., Smeets, F., Drukker, M., Lieverse, R., Lataster, T., Viechtbauer, W., et al. Childhood adversities increase the risk of psychosis: A meta-analysis of patient-control, prospective- and cross-sectional cohort studies. Schizophr Bull 38 (2012), 661–671.
39. 39 Cantor-Graae, E., Selten, J., Schizophrenia and migration : A meta-analysis and review. Am J Psychiatry 162 (2005), 12–24.
40. 40 McGrath, J., Saha, S., Welham, J., El Saadi, O., MacCauley, C., Chant, D., A systematic review of the incidence of schizophrenia: The distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med, 2, 2004, 13.
41. 41 Day, R., Nielsen, J.A., Korten, A., Ernberg, G., Dube, K.C., Gebhart, J., et al. Stressful life events preceding the acute onset of schizophrenia: A cross-national study from the World Health Organization. Cult Med Psychiatry 11 (1987), 123–205.
42. 42 Lataster, J., Myin-Germeys, I., Lieb, R., Wittchen, H.U., van Os, J., Adversity and psychosis: A 10-year prospective study investigating synergism between early and recent adversity in psychosis. Acta Psychiatr Scand 125 (2012), 388–399.
43. 43 Reininghaus, U., Kempton, M.J., Valmaggia, L., Craig, T.K.J., Garety, P., Onyejiaka, A., et al. Stress sensitivity, aberrant salience, and threat anticipation in early psychosis: An experience sampling study. Schizophr Bull 42 (2016), 702–722.
44. 44 Pycock, C.J., Kerwin, R.W., Carter, C.J., Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature 286 (1980), 74–76.
45. 45 Pani, L., Porcella, A., Gessa, G.L., The role of stress in the pathophysiology of the dopaminergic system. Mol Psychiatry 5 (2000), 14–21.
46. 46 Del Arco, A., Mora, F., Prefrontal cortex-nucleus accumbens interaction: In vivo modulation by dopamine and glutamate in the prefrontal cortex. Pharmacol Biochem Behav 90 (2008), 226–235.
47. 47 Gresch, P.J., Sved, A.F., Zigmond, M.J., Finlay, J.M., Stress-induced sensitization of dopamine and norepinephrine efflux in medial prefrontal cortex of the rat. J Neurochem 63 (1994), 575–583.
48. 48 Mizoguchi, K., Yuzurihara, M., Ishige, A., Sasaki, H., Chui, D.H., Tabira, T., Chronic stress induces impairment of spatial working memory because of prefrontal dopaminergic dysfunction. J Neurosci 20 (2000), 1568–1574.
49. 49 Imperato, A., Cabib, S., Puglisi-Alleggra, S., Repeated stressful experiences differently affect the time-dependent responses of the mesolimbic dopamine system to the stressor. Brain Res 601 (1993), 333–336.
50. 50 Cabib, S., Puglisi-Allegra, S., Opposite responses of mesolimbic dopamine system to controllable and uncontrollable aversive experiences. J Neurosci 14 (1994), 3333–3340.
51. 51 Cabib, S., Puglisi-Allegra, S., Stress, depression and the mesolimbic dopamine system. Psychopharmacology (Berl) 128 (1996), 331–342.
52. 52 Antelman, S.M., Eichler, A.J., Black, C.A., Kocan, D., Interchangeability of stress and amphetamine in sensitization. Science 207 (1980), 329–331.
53. 53 Pacchioni, A.M., Gioino, G., Assis, A., Cancela, L.M., A single exposure to restraint stress induces behavioral and neurochemical sensitization to stimulating effects of amphetamine: Involvement of NMDA receptors. Ann N Y Acad Sci 965 (2002), 233–246.
54. 54 Valenti, O., Gill, K.M., Grace, A.A., Different stressors produce excitation or inhibition of mesolimbic dopamine neuron activity: Response alteration by stress pre-exposure. Eur J Neurosci 35 (2012), 1312–1321.
55. 55 Brunelin, J., d'Amato, T., van Os, J., Cochet, A., Suaud-Chagny, M.F., Saoud, M., Effects of acute metabolic stress on the dopaminergic and pituitary-adrenal axis activity in patients with schizophrenia, their unaffected siblings and controls. Schizophr Res 100 (2008), 206–211.
56. 56 Myin-Germeys, I., Marcelis, M., Krabbendam, L., Delespaul, P., Van Os, J., Subtle fluctuations in psychotic phenomena as functional states of abnormal dopamine reactivity in individuals at risk. Biol Psychiatry 58 (2005), 105–110.
57. 57 Lataster, J., Collip, D., Ceccarini, J., Haas, D., Booij, L., van Os, J., et al. Psychosocial stress is associated with in vivo dopamine release in human ventromedial prefrontal cortex: A positron emission tomography study using [18F]fallypride. Neuroimage 58 (2011), 1081–1089.
58. 58 Nagano-Saito, A., Dagher, A., Booij, L., Gravel, P., Welfeld, K., Casey, K.F., et al. Stress-induced dopamine release in human medial prefrontal cortex–18F-fallypride/PET study in healthy volunteers. Synapse 67 (2013), 821–830.
59. 59 Kasanova, Z., Hernaus, D., Vaessen, T., van Amelsvoort, T., Winz, O., Heinzel, A., et al. Early-life stress affects stress-related prefrontal dopamine activity in healthy adults, but not in individuals with psychotic disorder. PLoS One, 11, 2016, e0150746.
60. 60 Lataster, J., Collip, D., Ceccarini, J., Hernaus, D., Haas, D., Booij, L., et al. Familial liability to psychosis is associated with attenuated dopamine stress signaling in ventromedial prefrontal cortex. Schizophr Bull 40 (2014), 66–77.
61. 61 Hernaus, D., Collip, D., Lataster, J., Viechtbauer, W., Myin, E., Ceccarini, J., Van Laere, K., van Os, J., Myin-Germeys, I., Psychotic reactivity to daily life stress and the dopamine system : A study combining experience sampling and [18F]fallypride positron emission tomography. J Abnorm Psychol 124 (2015), 27–37.
62. 62 Hernaus, D., Collip, D., Kasanova, Z., Winz, O., Heinzel, A., van Amelsvoort, T., et al. No evidence for attenuated stress-induced extrastriatal dopamine signaling in psychotic disorder. Transl Psychiatry, 5, 2015, e547.
63. 63 Soliman, A., O'Driscoll, G.A., Pruessner, J., Holahan, A.-L., Boileau, I., Gagnon, D., Dagher, A., Stress-induced dopamine release in humans at risk of psychosis: A [11C]raclopride PET study. Neuropsychopharmacology 33 (2008), 2033–2041.
64. 64 Egerton, A., Valmaggia, L.R., Howes, O.D., Day, F., Chaddock, C.A., Allen, P., et al. Adversity in childhood linked to elevated striatal dopamine function in adulthood. Schizophr Res 176 (2016), 171–176.
65. 65 Pruessner, J.C., Champagne, F., Meaney, M.J., Dagher, A., Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: A positron emission tomography study using [11C]raclopride. J Neurosci 24 (2004), 2825–2831.
66. 66 Oswald, L.M., Wand, G.S., Kuwabara, H., Wong, D.F., Zhu, S., Brasic, J.R., History of childhood adversity is positively associated with ventral striatal dopamine responses to amphetamine. Psychopharmacology (Berl) 231 (2014), 2417–2433.
67. 67 Gevonden, M., Booij, J., van den Brink, W., Heijtel, D., van Os, J., Selten, J.-P., Increased release of dopamine in the striata of young adults with hearing impairment and its relevance for the social defeat hypothesis of schizophrenia. JAMA Psychiatry 71 (2014), 1364–1372.
68. 68 Walker, E.F., Diforio, D., Schizophrenia: A neural diathesis-stress model. Psychol Rev 104 (1997), 667–685.
69. 69 Thompson, J.L., Pogue-Geile, M.F., Grace, A.A., Developmental pathology, dopamine, and stress: A model for the age of onset of schizophrenia symptoms. Schizophr Bull 30 (2004), 875–900.
70. 70 Ripke, S., Neale, B.M., Corvin, A., Walters, J.T., Farh, K.H., Holmans, P.A., et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature, 511(7510), 2014, 421.
71. 71 Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M., Tanabe, M., KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res 44 (2016), D457–D462.
72. 72 Edwards, A.C., Bacanu, S., Bigdeli, T.B., Moscati, A., Kendler, K.S., Evaluating the dopamine hypothesis of schizophrenia in a large-scale genome-wide association study. Schizophr Res 176 (2016), 136–140.
73. 73 Emamian, E.S., Hall, D., Birnbaum, M.J., Karayiorgou, M., Gogos, J.A., Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36 (2004), 131–137.
74. 74 Emamian, E.S., AKT/GSK3 signaling pathway and schizophrenia. Front Mol Neurosci, 5, 2012, 33.
75. 75 Beaulieu, J.-M., Gainetdinov, R.R., The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63 (2011), 182–217.
76. 76 van Os, J., Rutten, B.P., Poulton, R., Gene-environment interactions in schizophrenia: Review of epidemiological findings and future directions. Schizophr Bull 34 (2008), 1066–1082.
77. 77 van Os, J., Pedersen, C.B., Mortensen, P.B., Confirmation of synergy between urbanicity and familial liability in the causation of psychosis. Am J Psychiatry 161 (2004), 2312–2314.
78. 78 Hutchinson, G., Takei, N., Fahy, T.A., Bhugra, D., Gilvarry, C., Moran, P., et al. Morbid risk of schizophrenia in first-degree relatives of white and African-Caribbean patients with psychosis. Br J Psychiatry 169 (1996), 776–780.
79. 79 Shotbolt, P., Stokes, P.R., Owens, S.F., Toulopoulou, T., Picchioni, M.M., Bose, S.K., et al. Striatal dopamine synthesis capacity in twins discordant for schizophrenia. Psychol Med 41 (2011), 2331–2338.
80. 80 Huttunen, J., Heinimaa, M., Svirskis, T., Nyman, M., Kajander, J., Forsback, S., et al. Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia. Biol Psychiatry 63 (2008), 114–177.
81. 81 Hirvonen, J., van Erp, T.G.M., Huttunen, J., Aalto, S., Någren, K., Huttunen, M., et al. Brain dopamine d1 receptors in twins discordant for schizophrenia. Am J Psychiatry 163 (2006), 1747–1753.
82. 82 Hirvonen, J., van Erp, T.G.M., Huttunen, J., Aalto, S., Någren, K., Huttunen, M., et al. Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry 62 (2005), 371–378.
83. 83 Lee, K.J., Lee, J.S., Kim, S.J., Correll, C.U., Wee, H., Yoo, S.Y., et al. Loss of asymmetry in D2 receptors of putamen in unaffected family members at increased genetic risk for schizophrenia. Acta Psychiatr Scand 118 (2008), 200–208.
84. 84 Bassett, A.S., Chow, E.W.C., Schizophrenia and 22q11.2 deletion syndrome. Curr Psychiatry Rep 10 (2008), 148–157.
85. 85 Farrell, M.S., Werge, T., Sklar, P., Owen, M.J., Ophoff, R.A., O'Donovan, M.C., et al. Evaluating historical candidate genes for schizophrenia. Mol Psychiatry 20 (2015), 555–562.
86. 86 Bilder, R.M., Volavka, J., Lachman, H.M., Grace, A.A., The catechol-O-methyltransferase polymorphism: Relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 29 (2004), 1943–1961.
87. 87 Slifstein, M., Kolachana, B., Simpson, E.H., Tabares, P., Cheng, B., Duvall, M., et al. COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET. Mol Psychiatry 13 (2008), 821–827.
88. 88 Hirvonen, M.M., Någren, K., Rinne, J.O., Pesonen, U., Vahlberg, T., Hagelberg, N., Hietala, J., COMT Val158Met genotype does not alter cortical or striatal dopamine D2 receptor availability in vivo. Mol Imaging Biol 12 (2010), 192–197.
89. 89 Hernaus, D., Collip, D., Lataster, J., Ceccarini, J., Kenis, G., Booij, L., et al. COMT Val158Met genotype selectively alters prefrontal [18F]fallypride displacement and subjective feelings of stress in response to a psychosocial stress challenge. PLoS One, 8, 2013, e65662.
90. 90 Arnsten, A.F., Stress signalling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci 10 (2010), 410–422.
91. 91 Buckert, M., Kudielka, B.M., Reuter, M., Fiebach, C.J., The COMT Val158Met polymorphism modulates working memory performance under acute stress. Psychoneuroendocrinology 37 (2012), 1810–1821.
92. 92 Qin, S., Cousijn, H., Rijpkema, M., Luo, J., Franke, B., Hermans, E.J., Fernández, G., The effect of moderate acute psychological stress on working memory-related neural activity is modulated by a genetic variation in catecholaminergic function in humans. Front Integr Neurosci, 6, 2012, 16.
93. 93 Rabl, U., Meyer, B.M., Diers, K., Bartova, L., Berger, A., Mandorfer, D., et al. Additive gene-environment effects on hippocampal structure in healthy humans. J Neurosci 34 (2014), 9917–9926.
94. 94 Ursini, G., Bollati, V., Fazio, L., Porcelli, A., Iacovelli, L., Catalani, A., et al. Stress-related methylation of the catechol-O-methyltransferase Val158 allele predicts human prefrontal cognition and activity. J Neurosci 31 (2011), 6692–6698.
95. 95 Pecina, M., Martinez-Jauand, M., Love, T., Heffernan, J., Montoya, P., Hodgkinson, C., et al. Valence-specific effects of BDNF Val66Met polymorphism on dopaminergic stress and reward processing in humans. J Neurosci 34 (2014), 5874–5881.
96. 96 Simons, C.J., Wichers, M., Derom, C., Thiery, E., Myin-Germeys, I., Krabbendam, L., van Os, J., Subtle gene-environment interactions driving paranoia in daily life. Genes Brain Behav 8 (2009), 5–12.
97. 97 Peciña, M., Mickey, B.J., Love, T., Wang, H., Langenecker, S.A., Hodgkinson, C., et al. DRD2 polymorphisms modulate reward and emotion processing, dopamine neurotransmission and openness to experience. Cortex 49 (2013), 877–890.
98. 98 Lovic, V., Belay, H., Walker, C.-D., Burton, C.L., Meaney, M.J., Sokolowski, M., Fleming, A.S., Early postnatal experience and DRD2 genotype affect dopamine receptor expression in the rat ventral striatum. Behav Brain Res 237 (2013), 278–282.
99. 99 Talkowski, M.E., Kirov, G., Bamne, M., Georgieva, L., Torres, G., Mansour, H., et al. A network of dopaminergic gene variations implicated as risk factors for schizophrenia. Hum Mol Genet 17 (2008), 747–758.
100. 100 Bly, M., Mutation in the vesicular monoamine gene, SLC18A1, associated with schizophrenia. Schizophr Res 78 (2005), 337–338.
101. 101 Hoogendoorn, M.L., Bakker, S.C., Schnack, H.G., Selten, J.-P., Otten, H.G., Verduijn, W., et al. No association between 12 dopaminergic genes and schizophrenia in a large Dutch sample. Am J Med Genet Part B Neuropsychiatr Genet 134B (2005), 6–9.
102. 102 Ishizuka, K., Paek, M., Kamiya, A., Sawa, A., A review of disrupted-in-schizophrenia-1 (DISC1): Neurodevelopment, cognition, and mental conditions. Biol Psychiatry 59 (2006), 1189–1197.
103. 103 Brennand, K.J., Simone, A., Jou, J., Gelboin-Burkhart, C., Tran, N., Sangar, S., et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 473 (2011), 221–225.
104. 104 Brandon, N.J., Sawa, A., Linking neurodevelopmental and synaptic theories of mental illness through DISC1 12 (2011), 707–722.
105. 105 Niwa, M., Jaaro-Peled, H., Tankou, S., Seshadri, S., Hikida, T., Matsumoto, Y., et al. Adolescent stress-induced epigenetic control of dopaminergic neurons via glucocorticoids. Science339, 2013, 335–339.
106. 106 Millar, J.K., Pickard, B.S., Mackie, S., James, R., Christie, S., Buchanan, S.R., et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 310 (2005), 1187–1191.
107. 107 Deng, X., Takaki, H., Wang, L., Kuroki, T., Nakahara, T., Hashimoto, K., et al. Positive association of phencyclidine-responsive genes, PDE4A and PLAT, with schizophrenia. Am J Med Genet Part B Neuropsychiatr Genet 156B (2011), 850–858.
108. 108 Gamo, N.J., Duque, A., Paspalas, C.D., Kata, A., Fine, R., Boven, L., et al. Role of disrupted in schizophrenia 1 (DISC1) in stress-induced prefrontal cognitive dysfunction. Transl Psychiatry, 3, 2013, e328.
109. 109 Hall, J., Trent, S., Thomas, K.L., O'Donovan, M.C., Owen, M.J., Genetic risk for schizophrenia: Convergence on synaptic pathways involved in plasticity. Biol Psychiatry 77 (2014), 52–58.
110. 110 Howes, O., McCutcheon, R., Stone, J., Glutamate and dopamine in schizophrenia : An update for the 21st century. J Psychopharmacol 29 (2015), 97–115.
111. 111 Vernaleken, I., Klomp, M., Moeller, O., Raptis, M., Nagels, A., Rösch, F., et al. Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availability. Int J Neuropsychopharmacol 16 (2013), 745–754.
112. 112 Jackson, M.E., Homayoun, H., Moghaddam, B., NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci U S A 101 (2004), 8467–8472.
113. 113 Weinstein, J.J., Chohan, M.O., Slifstein, M., Kegeles, L.S., Moore, H., Abi-Dargham, A., Pathway-specific dopamine abnormalities in schizophrenia. Biol Psychiatry 81 (2017), 31–41.
114. 114 Hook, V., Brennand, K.J., Kim, Y., Toneff, T., Funkelstein, L., Lee, K.C., et al. Human iPSC neurons display activity-dependent neurotransmitter secretion: Aberrant catecholamine levels in schizophrenia neurons. Stem Cell Reports 3 (2014), 531–538.
115. 115 Popoli, M., Yan, Z., McEwen, B.S., Sanacora, G., The stressed synapse: The impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci 13 (2012), 22–37.
116. 116 Pocklington, A.J., Rees, E., Walters, J.T., Han, J., Kavanagh, D.H., Chambert, K.D., et al. Novel findings from CNVs implicate inhibitory and excitatory signaling complexes in schizophrenia. Neuron 86 (2015), 1203–1214.
117. 117 Ginovart, N., Kapur, S., Rolel of dopamine D(2) receptors for antipsychotic activity. Handb Exp Pharmacol 212 (2012), 27–52.
118. 118 Demjaha, A., Murray, R.M., McGuire, P.K., Kapur, S., Howes, O.D., Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry 169 (2012), 1203–1210.
119. 119 Ipser, J.C., Stein, D.J., Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). Int J Neuropsychopharmacol 15 (2012), 825–840.
120. 120 Vidal, C., Reese, C., Fischer, B.A., Chiapelli, J., Himelhoch, S., Meta-analysis of efficacy of mirtazapine as an adjunctive treatment of negative symptoms in schizophrenia. Clin Schizophr Relat Psychoses 9 (2015), 88–95.
121. 121 Thompson, J.L., Urban, N., Slifstein, M., Xu, X., Kegeles, L.S., Girgis, R.R., et al. Striatal dopamine release in schizophrenia comorbid with substance dependence. Mol Psychiatry 18 (2013), 909–915.
122. 122 Bloomfield, M.A., Morgan, C.J., Egerton, A., Kapur, S., Curran, H.V., Howes, O.D., Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry 75 (2014), 470–478.
123. 123 Potvin, S., Pampoulova, T., Mancini-Marië, A., Lipp, O., Bouchard, R.-H., Stip, E., Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. J Neurol Neurosurg Psychiatry 77 (2006), 796–798.
124. 124 Stefanis, N.C., Henquet, C., Avramopoulos, D., Smyrnis, N., Evdokimidis, I., Myin-Germeys, I., et al. COMT Val158Met moderation of stress-induced psychosis. Psychol Med 37 (2007), 1651–1656.
125. 125 Ira, E., De Santi, K., Lasalvia, A., Bonetto, C., Zanatta, G., Cristofalo, D., et al. Positive symptoms in first-episode psychosis patients experiencing low maternal care and stressful life events: A pilot study to explore the role of the COMT gene. Stress 17 (2014), 410–415.
126. 126 Molero, P., Ortuño, F., Zalacain, M., Patiño-García, A., Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: Influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogenomics J 7 (2007), 418–426.
127. 127 Collip, D., van Winkel, R., Peerbooms, O., Lataster, T., Thewissen, V., Lardinois, M., et al. COMT Val158Met-stress interaction in psychosis: Role of background psychosis risk. CNS Neurosci Ther 17 (2011), 612–619.
128. 128 van Winkel, R., Henquet, C., Rosa, A., Papiol, S., Fananás, L., De Hert, M., et al. Evidence that the COMT(Val158Met) polymorphism moderates sensitivity to stress in psychosis: An experience-sampling study. Am J Med Genet Part B Neuropsychiatr Genet 147B (2008), 10–17.
129. 129 Lewis, D.A., Hashimoto, T., Volk, D.W., Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6 (2005), 312–324.
130. 130 de la Fuente-Sandoval, C., León-Ortiz, P., Favila, R., Stephano, S., Mamo, D., Ramírez-Bermúdez, J., Graff-Guerrero, A., Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology 36 (2011), 1781–1791.
131. 131 Stone, J.M., Howes, O.D., Egerton, A., Kambeitz, J., Allen, P., Lythgoe, D.J., et al. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biol Psychiatry, 68, 2010 Elsevier Inc.599–602.
132. 132 Abi-Dargham, A., Kegeles, L.S., Zea-Ponce, Y., Mawlawi, O., Martinez, D., Mitropoulou, V., et al. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol Psychiatry 55 (2004), 1001–1006.
133. 133 Soliman, A., O'Driscoll, G.A., Pruessner, J., Holahan, A.-L.V., Boileau I, Gagnon, D., Dagher, A., Stress-induced dopamine release in humans at risk of psychosis: A [11C]raclopride PET study. Neuropsychopharmacology 33 (2008), 2033–2041.
134. 134 Brunelin, J., d'Amato, T., Van Os, J., Costes, N., Suaud Chagny, M.-F., Saoud, M., Increased left striatal dopamine transmission in unaffected siblings of schizophrenia patients in response to acute metabolic stress. Psychiatry Res 181 (2010), 130–135.
135. 135 Hirvonen, J., van Erp, T.G.M., Huttunen, J., Någren, K., Huttunen, M., Aalto, S., et al. Striatal dopamine D1 and D2 receptor balance in twins at increased genetic risk for schizophrenia. Psychiatry Res 146 (2006), 13–20.